Medical news
-
Gene therapy—a dream come true?
Gene therapy for hemophilia: the once elusive promise of gene therapy may become a reality in the very near future. After decades of clinical work,...
-
WFH Notice: Global recall of Octim®/Octostim® desmopressin nasal spray (1.5 mg/ml) by Ferring Pharmaceuticals
Update to WFH Notice: recall of desmopressin nasal spray by Ferring Pharmaceuticals (July 20, 2020) August 4, 2020 In mid-July, Ferring Pharmaceuticals initiated a voluntary precautionary...
-
Now published: The WFH Guidelines for the Management of Hemophilia, 3rd edition
This 3rd edition of the World Federation of Hemophilia (WFH) Guidelines for the Management of Hemophilia offers up-to-date guidance and practical recommendations on the diagnosis and management...
-
WFH Notice: recall of desmopressin nasal spray by Ferring Pharmaceuticals
July 20, 2020 The WFH has learned of a voluntary product recall of desmopressin nasal spray by Ferring Pharmaceuticals, due to out of specification results...
-
Joint WFH and NHF statement issued regarding two deaths reported in orphan disease gene therapy clinical trial
A joint World Federation of Hemophilia (WFH) and National Hemophilia Foundation (NHF) statement* is issued on two deaths reported in orphan disease gene therapy clinical...
